EMBO Molecular Medicine (Mar 2015)
Genetic and hypoxic alterations of the microRNA‐210‐ISCU1/2 axis promote iron–sulfur deficiency and pulmonary hypertension
- Kevin White,
- Yu Lu,
- Sofia Annis,
- Andrew E Hale,
- B Nelson Chau,
- James E Dahlman,
- Craig Hemann,
- Alexander R Opotowsky,
- Sara O Vargas,
- Ivan Rosas,
- Mark A Perrella,
- Juan C Osorio,
- Kathleen J Haley,
- Brian B Graham,
- Rahul Kumar,
- Rajan Saggar,
- Rajeev Saggar,
- W Dean Wallace,
- David J Ross,
- Omar F Khan,
- Andrew Bader,
- Bernadette R Gochuico,
- Majed Matar,
- Kevin Polach,
- Nicolai M Johannessen,
- Haydn M Prosser,
- Daniel G Anderson,
- Robert Langer,
- Jay L Zweier,
- Laurence A Bindoff,
- David Systrom,
- Aaron B Waxman,
- Richard C Jin,
- Stephen Y Chan
Affiliations
- Kevin White
- Divisions of Cardiovascular Medicine and Network Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School
- Yu Lu
- Divisions of Cardiovascular Medicine and Network Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School
- Sofia Annis
- Divisions of Cardiovascular Medicine and Network Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School
- Andrew E Hale
- Divisions of Cardiovascular Medicine and Network Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School
- B Nelson Chau
- Regulus Therapeutics
- James E Dahlman
- Institute for Medical Engineering and Science, Massachusetts Institute of Technology
- Craig Hemann
- The Davis Heart and Lung Research Institute, Division of Cardiovascular Medicine, Department of Internal Medicine, Wexner Medical Center, The Ohio State University
- Alexander R Opotowsky
- Divisions of Cardiovascular Medicine and Network Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School
- Sara O Vargas
- Department of Pathology, Boston Children's Hospital, Harvard Medical School
- Ivan Rosas
- Division of Pulmonary/Critical Care Medicine, Department of Medicine, Harvard Medical School
- Mark A Perrella
- Division of Pulmonary/Critical Care Medicine, Department of Medicine, Harvard Medical School
- Juan C Osorio
- Division of Pulmonary/Critical Care Medicine, Department of Medicine, Harvard Medical School
- Kathleen J Haley
- Division of Pulmonary/Critical Care Medicine, Department of Medicine, Harvard Medical School
- Brian B Graham
- Program in Translational Lung Research, University of Colorado
- Rahul Kumar
- Program in Translational Lung Research, University of Colorado
- Rajan Saggar
- Departments of Medicine and Pathology, David Geffen School of Medicine, University of California, Los Angeles
- Rajeev Saggar
- Department of Cardiothoracic Surgery, University of Arizona College of Medicine
- W Dean Wallace
- Departments of Medicine and Pathology, David Geffen School of Medicine, University of California, Los Angeles
- David J Ross
- Departments of Medicine and Pathology, David Geffen School of Medicine, University of California, Los Angeles
- Omar F Khan
- Department of Chemical Engineering, Massachusetts Institute of Technology
- Andrew Bader
- Institute for Medical Engineering and Science, Massachusetts Institute of Technology
- Bernadette R Gochuico
- Medical Genetics Branch, National Human Genome Research Institute, National Institutes of Health
- Majed Matar
- Celsion‐EGEN, Inc.
- Kevin Polach
- Celsion‐EGEN, Inc.
- Nicolai M Johannessen
- Department of Cardiology, University of Bergen
- Haydn M Prosser
- The Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus
- Daniel G Anderson
- Institute for Medical Engineering and Science, Massachusetts Institute of Technology
- Robert Langer
- Institute for Medical Engineering and Science, Massachusetts Institute of Technology
- Jay L Zweier
- The Davis Heart and Lung Research Institute, Division of Cardiovascular Medicine, Department of Internal Medicine, Wexner Medical Center, The Ohio State University
- Laurence A Bindoff
- Department of Clinical Medicine, University of Bergen
- David Systrom
- Division of Pulmonary/Critical Care Medicine, Department of Medicine, Harvard Medical School
- Aaron B Waxman
- Division of Pulmonary/Critical Care Medicine, Department of Medicine, Harvard Medical School
- Richard C Jin
- Divisions of Cardiovascular Medicine and Network Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School
- Stephen Y Chan
- Divisions of Cardiovascular Medicine and Network Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School
- DOI
- https://doi.org/10.15252/emmm.201404511
- Journal volume & issue
-
Vol. 7,
no. 6
pp. 695 – 713
Abstract
Abstract Iron–sulfur (Fe‐S) clusters are essential for mitochondrial metabolism, but their regulation in pulmonary hypertension (PH) remains enigmatic. We demonstrate that alterations of the miR‐210‐ISCU1/2 axis cause Fe‐S deficiencies in vivo and promote PH. In pulmonary vascular cells and particularly endothelium, hypoxic induction of miR‐210 and repression of the miR‐210 targets ISCU1/2 down‐regulated Fe‐S levels. In mouse and human vascular and endothelial tissue affected by PH, miR‐210 was elevated accompanied by decreased ISCU1/2 and Fe‐S integrity. In mice, miR‐210 repressed ISCU1/2 and promoted PH. Mice deficient in miR‐210, via genetic/pharmacologic means or via an endothelial‐specific manner, displayed increased ISCU1/2 and were resistant to Fe‐S‐dependent pathophenotypes and PH. Similar to hypoxia or miR‐210 overexpression, ISCU1/2 knockdown also promoted PH. Finally, cardiopulmonary exercise testing of a woman with homozygous ISCU mutations revealed exercise‐induced pulmonary vascular dysfunction. Thus, driven by acquired (hypoxia) or genetic causes, the miR‐210‐ISCU1/2 regulatory axis is a pathogenic lynchpin causing Fe‐S deficiency and PH. These findings carry broad translational implications for defining the metabolic origins of PH and potentially other metabolic diseases sharing similar underpinnings.
Keywords